<DOC>
	<DOCNO>NCT01363700</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy DE-114 ophthalmic solution compare Placebo Olopatadine hydrochloride 0.1 % ophthalmic solution patient allergic conjunctivitis .</brief_summary>
	<brief_title>Study DE-114 Ophthalmic Solution Patients With Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Provided sign , write informed consent . Has positive result allergenspecific IgE antibody test . If subject female childbearing potential , must utilize reliable contraceptive throughout study , must negative urine pregnancy test prior enrollment study . Females pregnant , nurse planning pregnancy , females childbearing potential use reliable method contraception . Presence abnormality significant illness could expect interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>